NeurAxis to Host Second Quarter 2024 Results and Business Update Call on Friday, August 9, 2024
NeurAxis, Inc. (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic conditions in children and adults, has announced its upcoming second quarter 2024 financial results release and conference call. The company will report summarized financial results for the quarter ended June 30, 2024, on Friday, August 9, 2024, before market open. A conference call is scheduled for the same day at 9:00 am ET to review the results.
Interested parties can access the call via a live webcast available on the company's Investor Relations website. Participants can also join through a call-in option by registering online. A webcast replay will be available after the call on the company's website for those unable to attend live.
NeurAxis, Inc. (NYSE American: NRXS), un'azienda di tecnologia medica focalizzata sulle terapie di neuromodulazione per condizioni croniche nei bambini e negli adulti, ha annunciato la prossima pubblicazione dei risultati finanziari del secondo trimestre 2024 e una conference call. L'azienda riporterà i risultati finanziari riassunti per il trimestre concluso il 30 giugno 2024, venerdì 9 agosto 2024, prima dell'apertura del mercato. Una conference call è programmata per lo stesso giorno alle 9:00 AM ET per esaminare i risultati.
Le parti interessate possono accedere alla call tramite un webcast in diretta disponibile sul sito web delle Relazioni con gli Investitori dell'azienda. I partecipanti possono anche unirsi attraverso un'opzione di chiamata prenotando online. Una registrazione del webcast sarà disponibile dopo la call sul sito dell'azienda per coloro che non possono partecipare dal vivo.
NeurAxis, Inc. (NYSE American: NRXS), una empresa de tecnología médica centrada en terapias de neuromodulación para condiciones crónicas en niños y adultos, ha anunciado la próxima publicación de los resultados financieros del segundo trimestre de 2024 y una conferencia telefónica. La empresa informará sobre los resultados financieros resumidos para el trimestre que finalizó el 30 de junio de 2024, el viernes 9 de agosto de 2024, antes de la apertura del mercado. Se ha programado una conferencia telefónica para el mismo día a las 9:00 AM ET para revisar los resultados.
Las partes interesadas pueden acceder a la llamada a través de un webcast en vivo disponible en el sitio web de Relaciones con Inversores de la empresa. Los participantes también pueden unirse a través de una opción de llamada registrándose en línea. Una repetición del webcast estará disponible después de la llamada en el sitio web de la empresa para aquellos que no puedan asistir en vivo.
NeurAxis, Inc. (NYSE American: NRXS)는 아동과 성인을 위한 만성 질환에 대한 신경 조절 치료에 중점을 둔 의료 기술 회사로, 2024년 2분기 재무 결과 발표 및 컨퍼런스 콜을 곧 개최할 예정이라고 발표했습니다. 이 회사는 2024년 6월 30일 종료된 분기의 요약 재무 결과를 2024년 8월 9일 금요일, 시장 개장 전에 보고할 예정입니다. 결과를 검토하기 위해 같은 날 오전 9시 ET에 컨퍼런스 콜이 예정되어 있습니다.
관심 있는 당사자는 회사의 투자자 관계 웹사이트에서 제공되는 실시간 웹캐스트를 통해 콜에 접속할 수 있습니다. 참가자는 온라인 등록을 통해 전화로도 참여할 수 있습니다. 웹캐스트 재생은 실시간 참석이 불가능한 분들을 위해 콜 후 회사 웹사이트에서 제공될 예정입니다.
NeurAxis, Inc. (NYSE American: NRXS), une entreprise de technologie médicale axée sur les thérapies de neuromodulation pour les conditions chroniques chez les enfants et les adultes, a annoncé la prochaine publication de ses résultats financiers du deuxième trimestre 2024 et une conférence téléphonique. L'entreprise publiera un résumé des résultats financiers pour le trimestre se terminant le 30 juin 2024, le vendredi 9 août 2024, avant l'ouverture des marchés. Une conférence téléphonique est prévue pour le même jour à 9h00 ET pour examiner les résultats.
Les parties intéressées peuvent accéder à cet appel via un webcast en direct disponible sur le site des Relations Investisseurs de l'entreprise. Les participants peuvent également rejoindre via une option d'appel en s'inscrivant en ligne. Un replay du webcast sera disponible après l'appel sur le site de l'entreprise pour ceux qui ne peuvent pas y assister en direct.
NeurAxis, Inc. (NYSE American: NRXS), ein Medizintechnikunternehmen, das sich auf Neuromodulationstherapien für chronische Erkrankungen bei Kindern und Erwachsenen konzentriert, hat die bevorstehende Veröffentlichung der finanziellen Ergebnisse für das zweite Quartal 2024 und eine Telefonkonferenz angekündigt. Das Unternehmen wird die zusammenfassenden finanziellen Ergebnisse für das zum 30. Juni 2024 abgeschlossene Quartal am Freitag, den 9. August 2024, vor Markteröffnung bekannt geben. Eine Telefonkonferenz ist für denselben Tag um 9:00 Uhr ET vorgesehen, um die Ergebnisse zu besprechen.
Interessierte Parteien können die Konferenz über einen Live-Webcast auf der Investor-Relations-Website des Unternehmens verfolgen. Die Teilnehmer können auch über eine Anrufoption teilnehmen, indem sie sich online registrieren. Eine Webcast-Wiederholung wird nach dem Call auf der Website des Unternehmens für diejenigen verfügbar sein, die nicht live teilnehmen können.
- None.
- None.
CARMEL, Ind., Aug. 05, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its second quarter period ended June 30, 2024, on Friday, August 9, 2024, before market open. The Company has scheduled a conference call for the same day, Friday, August 9, 2024, at 9:00 am ET to review the results.
Conference Call Details
Date and Time: Friday, August 9, 2024, at 9:00am ET
Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at https://edge.media-server.com/mmc/p/bettcvsw or https://ir.neuraxis.com/. For participants listening through the webcast, questions can be sent in through the portal using the “Ask a Question” link or by emailing questions to NRXS@lythampartners.com.
Call-in Information: Interested parties can also access the live conference call by initially registering at the following link. Upon completion of the registration link, call-in participants will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.
Replay: A webcast replay will be available in the Investor Relations section of the Company's website at https://edge.media-server.com/mmc/p/bettcvsw or https://ir.neuraxis.com/.
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company’s stock, public health issues or other events, the Company’s compliance with applicable laws, the results of the Company’s clinical trials and perceptions thereof, the results of submissions to the FDA, the results of the shareholder vote to enable the issuance of the Preferred Stock, and factors described in the Risk Factors section of NeurAxis’s public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contacts:
Company
NeurAxis, Inc.
info@neuraxis.com
Investor Relations
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
FAQ
When will NeurAxis (NRXS) release its Q2 2024 financial results?
What time is the NeurAxis (NRXS) Q2 2024 earnings call scheduled for?
How can investors access the NeurAxis (NRXS) Q2 2024 earnings call?
Will there be a replay available for the NeurAxis (NRXS) Q2 2024 earnings call?
